Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - enalapril maleate - tablet - 10mg

Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - ibuprofen - suspension - 200 mg per 5 ml

Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - ibuprofen - suspension - 100 mg per 5 ml

Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - metfromin hydrochloride - film-coated tablet - 500 mg

Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - metformin hydrochloride - film-coated tablet - 850 mg

Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - thiamine hydrochloride , pyridoxine hydrochloride , cyanocobalamin - film-coated tablet - 100mg/ 20mg/ 200mcg

Filipini - angleščina - FDA (Food And Drug Administration)

hizon laboratories, inc. - telmisartan - tablet - 80 mg

Filipini - angleščina - FDA (Food And Drug Administration)

ascorbic acid , zinc - syrup (oral drops) - 50 mg / 5 mg (equiv. to 13.72 mg zinc sulfate monohydrate) per ml

Filipini - angleščina - FDA (Food And Drug Administration)

ascorbic acid , zinc - syrup - 100 mg / 10 mg (equiv. to 27.4 mg zinc sulfate monohydrate) per 5 ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

watson laboratories, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - tablet, extended release - 324 mg - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (seedosage and administration ), then quinidine gluconate should be discontinued. chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. in patients